文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

解毒利脉汤治疗热毒炽盛证脓毒症患者的疗效观察

[Effect of Jiedu Limai decoction in septic patients with syndrome of heat-toxin exuberance].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2021-01-01
一句话结论在指南标准治疗基础上加用解毒利脉汤(每日1次,14天)可改善热毒炽盛证脓毒症患者的凝血功能、心肾损伤标志物及炎症因子水平,并减少新发器官衰竭。

治疗7天后,干预组D-二聚体、Fib、FDP、PCT、CRP、IL-6、BNP、KIM-1水平均显著低于对照组(均P<0.05),新发器官衰竭比例降低(30.0% vs. 50.0%,P<0.05)。28天死亡率两组无统计学差异(18.0% vs. 24.0%,P>0.05)。提示该方剂可作为热毒炽盛证脓毒症的辅助治疗改善部分器官功能指标。

要点

  • 在指南标准治疗基础上加用解毒利脉汤,每日1次、疗程14天,适用于ICU收治的Sepsis-3热毒炽盛证脓毒症患者。
  • 治疗7天后干预组D-二聚体2.2(1.8, 8.5)mg/L、FDP 7.2(5.4, 10.2)mg/L、Fib 3.7(3.4, 4.3)g/L均显著低于对照组(P<0.05)。
  • 治疗7天后干预组PCT 0.4(0.2, 2.9)μg/L、CRP 50.1(9.5, 116.0)mg/L、IL-6 31.6(21.6, 81.0)ng/L均显著低于对照组(P<0.05)。
  • 干预组新发器官衰竭比例30.0% vs. 对照组50.0%(P<0.05),BNP与KIM-1水平亦显著降低(P<0.05)。
  • 28天死亡率干预组18.0% vs. 对照组24.0%,差异无统计学意义(P>0.05)。

适用人群与场景

  • 纳入:2019年3月至2020年4月上海交通大学附属第一人民医院及松江分院ICU收治的感染或临床诊断感染、符合Sepsis-3诊断标准且中医辨证为热毒炽盛证的脓毒症患者。
  • 排除:不符合Sepsis-3诊断标准、年龄>80岁或<18岁、多发肿瘤转移、自身免疫系统疾病、ICU停留时间<24小时、急性活动性消化道出血、数据不完整者。

诊断标准与关键阈值

  • 纳入标准基于Sepsis-3诊断标准(原文未列出具体SOFA评分界值)及中医热毒炽盛证辨证。
  • 排除标准包括年龄>80岁或<18岁、多发肿瘤转移、自身免疫系统疾病、ICU停留<24小时、急性活动性消化道出血、数据不完整。

处置流程与药物剂量

  • 两组均按指南给予标准治疗。
  • 解毒利脉汤组在标准治疗基础上加用解毒利脉汤,每日1次,疗程14天(原文未提供方剂组成、剂量及给药途径)。
  • 治疗前后监测APACHE II评分、SOFA评分、凝血指标、感染指标、炎症因子及器官功能指标。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 干预:标准治疗+解毒利脉汤(每日1次×14天)vs. 标准治疗。
  • 治疗7天后干预组凝血指标(D-二聚体、Fib、FDP)、感染标志物(PCT、CRP)、炎症因子(IL-6)均显著低于对照组(均P<0.05)。
  • 治疗7天后干预组BNP 261.1(87.5, 360.3)ng/L vs. 对照组347.3(128.8, 439.4)ng/L,KIM-1 0.86(0.01, 1.40)μg/L vs. 1.24(1.05, 1.57)μg/L,均P<0.05。
  • 新发器官衰竭:干预组30.0% vs. 对照组50.0%(P<0.05)。
  • 28天死亡率:干预组18.0% vs. 对照组24.0%(P>0.05,差异无统计学意义)。

证据类型、等级与局限

  • 证据类型:前瞻性随机对照试验。

对床旁实践的改变

  • 对ICU收治的Sepsis-3热毒炽盛证脓毒症患者,可考虑在指南标准治疗基础上加用解毒利脉汤(每日1次×14天)以改善凝血功能、心肾损伤标志物及炎症因子水平,并可能减少新发器官衰竭。
  • 该方剂对28天死亡率的影响在本研究中未显示统计学差异,不能据此推荐其用于降低死亡率。
  • 适用人群为18-80岁、无多发肿瘤转移、无自身免疫系统疾病、无急性活动性消化道出血且ICU停留≥24小时的脓毒症患者;不适用于排除标准所列人群。
  • 原文未提供方剂组成、剂量及给药途径,临床无法直接复制具体方案。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the clinical effect of Jiedu Limai decoction in septic patients with syndrome of heat-toxin exuberance.

METHODS: A prospective randomized controlled trial was conducted. From March 2019 to April 2020, septic patients with syndrome of heat-toxin exuberance admitted to intensive care unit (ICU) of Shanghai General Hospital and Songjiang Branch of Shanghai General Hospital were enrolled as the research objects, and they were divided into routine treatment group and Jiedu Limai decoction group by the random number table method. Patients in both groups were given standard treatment in accordance with the guidelines, and patients in the Jiedu Limai decoction group were given Jiedu Limai decoction in addition to the standard treatment, once a day for 14 days. The 28-day survival of patients of the two groups were recorded, the acute physiology and chronic health evaluation II (APACHE II) score, sequential organ failure assessment (SOFA) score, coagulation indexes, infection indexes, inflammatory cytokines and organ function indicators before treatment and 7 days after treatment in both groups were recorded, and the prognosis of the two groups were recorded.

RESULTS: A total of 259 patients with infection or clinical diagnosis of infection admitted during the experimental observation period were included, and those who did not meet the Sepsis-3 diagnostic criteria, more than 80 years old or less than 18 years old, with multiple tumor metastases, autoimmune system diseases, with length of ICU stay less than 24 hours, with acute active gastrointestinal bleeding and with incomplete data were excluded. One hundred patients were finally enrolled, with 50 patients in the routine treatment group and 50 patients in the Jiedu Limai decoction group. There were no statistically significant differences in coagulation indexes, infection indicators, inflammatory cytokines and organ function indicators before treatment between the two groups. After 7 days of treatment, the coagulation indexes, infection biomarkers and inflammatory cytokines in the Jiedu Limai decoction group were significantly lower than those in the routine treatment group [D-dimer (mg/L): 2.2 (1.8, 8.5) vs. 4.0 (1.5, 8.7), fibrinogen (Fib, g/L): 3.7 (3.4, 4.3) vs. 4.2 (3.7, 4.3), fibrinogen degradation product (FDP, mg/L): 7.2 (5.4, 10.2) vs. 13.2 (9.2, 15.2), procalcitonin (PCT, μg/L): 0.4 (0.2, 2.9) vs. 0.5 (0.2, 0.9), C-reactive protein (CRP, mg/L): 50.1 (9.5, 116.0) vs. 75.1 (23.5, 115.2), interleukin-6 (IL-6, ng/L): 31.6 (21.6, 81.0) vs. 44.1 (14.0, 71.3), all P < 0.05], and the levels of B-type brain natriuretic peptide (BNP) and kidney injury molecule-1 (KIM-1) were significantly lowered [BNP (ng/L): 261.1 (87.5, 360.3) vs. 347.3 (128.8, 439.4), KIM-1 (μg/L): 0.86 (0.01, 1.40) vs. 1.24 (1.05, 1.57), both P < 0.05]. Compared with the routine treatment group, the number of new organ failure in the Jiedu Limai decoction group was decreased (30.0% vs. 50.0%, P < 0.05). Although there was no significant difference in 28-day mortality between the two groups (P > 0.05), the 28-day mortality in the Jiedu Limai decoction group was lower than that in the routine treatment group (18.0% vs. 24.0%).

CONCLUSIONS: Combining Jiedu Limai decoction to the sepsis guideline in treating syndrome of heat-toxin exuberance can effectively improve patients' coagulation function, the situation of heart and renal injury, reduce the level of inflammatory cytokines, and fewer people develop new organ failure after treatment.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Li C, Xie Y, Zheng Z, et al. [Effect of Jiedu Limai decoction in septic patients with syndrome of heat-toxin exuberance]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021. PMID: 34412750. doi:10.3760/cma.j.cn121430-20201228-00776

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。